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Comparison of the Hemodynamic Performance
of Percutaneous and Surgical Bioprostheses
for the Treatment of Severe Aortic Stenosis
Marie-Annick Clavel, DVM, MSC,* John G. Webb, MD,† Philippe Pibarot, DVM, PHD,*
Lukas Altwegg, MD,† Eric Dumont, MD,* Chris Thompson, MD,† Robert De Larochellière, MD,*
Daniel Doyle, MD,* Jean-Bernard Masson, MD,† Sebastien Bergeron, MD,*
Olivier F. Bertrand, MD, PHD,* Josep Rodés-Cabau, MD*
Québec City, Québec, and Vancouver, British Columbia, Canada
Objectives This study was undertaken to compare the hemodynamic performance of a percutaneous bioprosthesis to that
of surgically implanted (stented and stentless) bioprostheses for the treatment of severe aortic stenosis.
Methods Fifty patients who underwent percutaneous aortic valve implantation (PAVI) with the Cribier-Edwards or Edwards
SAPIEN bioprosthetic valve (Edwards Lifesciences, Inc., Irvine, California) were matched 1:1 for sex, aortic annu-
lus diameter, left ventricular ejection fraction, body surface area, and body mass index, with 2 groups of 50 pa-
tients who underwent surgical aortic valve replacement (SAVR) with a stented valve (Edwards Perimount Magna
[SAVR-ST group]), or a stentless valve (Medtronic Freestyle, Medtronic, Minneapolis, Minnesota [SAVR-SL group]).
Doppler echocardiographic data were prospectively obtained before the intervention, at discharge, and at 6- to
12-month follow-up.
Results Mean transprosthetic gradient at discharge was lower (p  0.001) in the PAVI group (10  4 mm Hg) compared
with the SAVR-ST (13  5 mm Hg) and SAVR-SL (14  6 mm Hg) groups. Aortic regurgitation (AR) occurred
more frequently in the PAVI group (mild: 42%, moderate: 8%) compared with the SAVR-ST (mild: 10%, moder-
ate: 0%) and SAVR-SL (mild: 12%, moderate: 0%) groups (p  0.0001). At follow-up, the mean gradient in the
PAVI group remained lower (p  0.001) than that of the SAVR-ST group, but was similar to that of the SAVR-SL
group. The incidence of severe prosthesis-patient mismatch was significantly lower (p  0.007) in the PAVI
group (6%) compared with the SAVR-ST (28%) and SAVR-SL (20%) groups. However, the incidence of AR re-
mained higher (p  0.0001) in the PAVI group compared with the 2 other groups.
Conclusions PAVI provided superior hemodynamic performance compared with the surgical bioprostheses in terms of
transprosthetic gradient and prevention of severe prosthesis-patient mismatch, but was associated with a higher
incidence of AR. (J Am Coll Cardiol 2009;53:1883–91) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.01.060a
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murgical aortic valve replacement (SAVR) is the treatment of
hoice for patients with symptomatic severe aortic stenosis.
wo main types of bioprostheses, stented and stentless valves,
rom the *Quebec Heart & Lung Institute/Laval Hospital, Laval University, Québec
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009, accepted January 25, 2009.re currently used for SAVR with excellent hemodynamic
esults in the vast majority of patients. However, the hemody-
amic performance of the prosthetic valves is not equivalent to
hat of the normal native valve, and consequently, a substantial
See page 1892
roportion of the patients are left with some degree of
rosthesis-patient mismatch (PPM) after SAVR (1). Impor-
antly, the occurrence of severe PPM, defined as an indexed
alve effective orifice area (EOAi) 0.65 cm2/m2, has been
ssociated with reduced functional improvement and increased
orbidity and mortality rates at short-term and midtermollow-up after SAVR (1–3).
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Percutaneous Versus Surgical Bioprostheses May 19, 2009:1883–91In recent years, percutaneous
aortic valve implantation (PAVI)
has emerged as an alternative to
the treatment of severe aortic ste-
nosis in patients considered at high
or prohibitive surgical risk (4–9).
This patient selection has led to
carrying out PAVI interventions
in very old patients with multi-
ple comorbidities and severely
calcified aortic valves. The Cribier-
Edwards or the Edwards SAPIEN
bioprosthesis (Edwards Lifesciences,
Inc., Irvine, California) is a balloon-
expandable percutaneous valve that
consists of a metallic structure of
stainless steel containing a bio-
ogical valve. Unlike SAVR, which involves the removal of
he native aortic valve before valve implantation, the mech-
nism of PAVI consists of the expansion of the stent
ontaining the new valve against the native calcified aortic
alve. The implantation of a percutaneous bioprosthesis
ithin a “left-in-place” severely calcified valve might lead to
ncomplete and/or irregular expansion of the prosthetic
alve (10), but preliminary acute and midterm hemody-
amic results obtained with PAVI have been promising,
ith low transprosthetic gradients and large prosthetic valve
ffective orifice area (EOA) in most patients, although some
egree of residual aortic regurgitation (AR), usually para-
alvular, is common after this procedure (4–9). However,
ow the hemodynamic results obtained with PAVI compare
o those obtained with SAVR remains unknown. The
bjective of this study was to compare the hemodynamic
erformance of a percutaneous bioprosthesis, the Edwards
Cribier or SAPIEN) valve, to that of surgically implanted
stented and stentless) bioprostheses for the treatment of
ymptomatic severe aortic stenosis.
ethods
he study included a total of 50 patients with symptomatic
evere aortic stenosis who underwent successful PAVI with the
ribier-Edwards or Edwards SAPIEN valve in St. Paul’s
ospital, Vancouver, British Columbia, Canada, and in the
uebec Heart & Lung Institute/Laval Hospital, Quebec City,
anada. All patients had complete clinical and echocardio-
raphic follow-up at 6 to 12 months, and were included in a
rospective registry database. These patients were obtained
rom a series of 89 consecutive patients who underwent PAVI,
fter excluding those who had unsuccessful PAVI (failure to
mplant the valve or procedural death, n  8), those who died
efore the 6-month to 1-year follow-up (n  13), and those
ith a follow-up either carried out in other centers or incom-
lete (n  18). The procedures were performed under com-
Abbreviations
and Acronyms
AR  aortic regurgitation
EOA  effective orifice
area
EOAi  indexed effective
orifice area
LVEF  left ventricular
ejection fraction
PAVI  percutaneous
aortic valve implantation
PPM  prosthesis-patient
mismatch
SAVR  surgical aortic
valve replacementassionate clinical use approved by the Department of Health wnd Welfare (Ottawa, Ontario, Canada), and all patients
igned informed consent for the procedures.
The 50 PAVI patients were case-matched with 50 patients
ho had undergone successful SAVR with a stented
arpentier-Edwards Perimount Magna bioprosthesis (Ed-
ards Lifesciences [SAVR-ST group]), and with 50 patients
ho had undergone successful SAVR with a stentless Freestyle
ioprosthesis (Medtronic, Minneapolis, Minnesota [SAVR-
L group]), from a prospective registry database including all
atients who had undergone SAVR in the Quebec Heart &
ung Institute/Laval Hospital since 1993. Each PAVI patient
as matched 1:1 with both a SAVR-ST and a SAVR-SL
atient for sex (exact match), aortic annulus diameter (within
.05 mm), and left ventricular ejection fraction (LVEF)
within 5%) as determined by echocardiography, body surface
rea (within 0.3 m2), and body mass index (within 5 kg/m2).
he presence of a bicuspid aortic valve was a contraindication for
AVI, and we therefore excluded patients with a bicuspid valve
rom the study. All clinical and echocardiographic data were
ollected prospectively at baseline, at hospital discharge, and at 6-
o 12-month follow-up. Some of the patients included in the
AVI group had already been included in 2 previous studies (5,7).
AVI procedures. PAVI was performed with the use of
he Cribier-Edwards valve or the Edwards SAPIEN valve,
hich are balloon-expandable prostheses that consist of a
ubular slotted stainless steel stent with an attached pericar-
ial trileaflet valve and fabric sealing cuff. Two valve sizes of
3- and 26-mm expanded diameter were available. The
rocedures were performed by transfemoral approach in 38
76%) patients and by transapical approach in 12 (24%)
sing techniques described in detail in previous reports
4–9). Briefly, the procedures were performed by a team of
nterventional cardiologists and cardiac surgeons, under
eneral anesthesia, without cardiopulmonary bypass, and
ith fluoroscopy and transesophageal echocardiography
uidance. The 23-mm valve was selected if the aortic
nnulus was between 16 and 21 mm by transesophageal
chocardiography, and the 26-mm valve was selected if the
ortic annulus was between 22 and 25 mm. Patients received
spirin (80 mg/day) indefinitely and clopidogrel (75 mg/
ay) for 3 to 6 months.
AVR procedures. The 2 surgical bioprostheses used in
his study were the Magna valve, which is a stented
ioprosthesis fabricated from bovine pericardium sheets
ounted on a stent (SAVR-ST group), and the Freestyle
alve, which is a stentless bioprosthesis manufactured from
he whole porcine aortic valve (SAVR-SL group). The
AVR interventions were performed through standard mid-
ine sternotomy with cardiopulmonary bypass. Excision of
he native aortic valve and annular debridement was per-
ormed in all cases before valve implantation. The size of
oth stented and stentless valves was determined by the
iameter of the aortic annulus as measured by pre-calibrated
ylindrical sizers and proprietary valve sizers. The Magna
stented) valve was implanted in the supra-annular position
ith interrupted, radial, noneverting, pledget-supported
s
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May 19, 2009:1883–91 Percutaneous Versus Surgical Bioprosthesesutures; whereas the Freestyle (stentless) valve was inserted
n subcoronary position using a 2-layer suture technique.
atients received aspirin (80 to 325 mg/day) for the first 12
ost-operative weeks.
oppler echocardiography. All patients in the 3 groups
nderwent a Doppler echocardiographic examination at
aseline before intervention, at hospital discharge, and at 6-
o 12-month follow-up. The following measurements were
btained in all patients: aortic annulus diameter, LVEF
alculated with the Simpson method, mean transvalvular
radient calculated with the Bernoulli formula, and the
alve EOA measured by the continuity equation. The EOA
as indexed for body surface area (EOAi), and the occur-
ence of severe PPM was defined as an EOAi 0.65
m2/m2 (1). The presence, degree, and type (paravalvular
ersus transvalvular) of AR was recorded in all patients. The
egree of AR was classified as follows: trivial, mild, mod-
rate, and severe (11,12).
tatistical analysis. Categorical variables were expressed as
ercentages and continuous variables as mean (SD) unless
therwise specified. For each outcome variable, the mixed
odel analysis was performed to analyze 3 experimental
actors: 1 associated to the subjects matched and analyzed as
andom block effects, 1 associated to the comparison among
rocedures (PAVI, SAVR-ST, SAVR-SL), and 1 linked to
he time period. The procedure and period time factors were
nalyzed as repeated measures factors with an interaction
erm between them. For dichotomous variables, a binomial
robability distribution function was obtained using the
ogit link transformation. Differences were considered sta-
istically significant when p  0.05. The data were analyzed
sing SAS statistical software, version 9.1.3 (SAS Institute
nc., Cary, North Carolina).
esults
aseline and procedural data. Baseline clinical and echo-
ardiographic data are shown in Table 1. The PAVI
atients were older (p  0.0001) compared with the
AVR-ST and SAVR-SL patients. The mean values of the
atching variables in the whole study population were as
Data of the Clinical and Echocardiographic Varia
Table 1 Data of the Clinical and Echocardio
PAVI (n  50)
Age, yrs 83 7
Male, n (%)‡ 27 (54)
Body surface area, m2‡ 1.76 0.25
Body mass index, kg/m2‡ 25.2 5.2
Aortic annulus diameter, mm‡ 20.2 2.0
Indexed annulus diameter, mm/m2‡ 11.6 1.3
LVEF, %‡ 54 16
Mean gradient, mm Hg 47 17
Effective orifice area, cm2 0.60 0.14
Indexed effective orifice area, cm2/m2 0.34 0.10
*Significant difference (p  0.05) versus PAVI. †Significant difference
LVEF  left ventricular ejection fraction; PAVI  percutaneous aortic valve
valve; SAVR-ST  surgical aortic valve replacement–stented valve.ollows: aortic annulus diameter: 20.1 mm; LVEF: 54%;
ody surface area: 1.7 m2; and body mass index: 26 kg/m2.
here were no significant differences in the values of mean
ransvalvular gradients between groups, but patients in the
AVI group had lower baseline EOAi values compared
ith both SAVR-ST and SAVR-SL groups (p  0.011).
Valve sizes grouped according to type of implanted valve
re shown in Table 2. About two-thirds of the PAVI
atients received a 26-mm valve, and one-third a 23-mm
alve. The 21- and 23-mm valves were the most commonly
mplanted in both the SAVR-ST (72%) and SAVR-SL
70%) groups. Aortic root enlargement and Bentall proce-
ures were not used in the SAVR patients because of the
otentially increased operative risk associated with these
rocedures, especially in the elderly population with calci-
ed aortic root.
oppler echocardiography data. Doppler echocardiogra-
hy data at hospital discharge are shown in Table 3. Mean
ransprosthetic gradient at discharge was lower (p  0.001)
n the PAVI group (10 4 mm Hg) than in the SAVR-ST
13  5 mm Hg) or SAVR-SL (14  6 mm Hg) groups;
nd EOA and EOAi were larger (p  0.01) in the PAVI
roup (1.61  0.40 cm2 and 0.90  0.26 cm2/m2, respec-
ively) than in the SAVR-ST (1.29  0.25 cm2 and 0.76 
.16 cm2/m2, respectively) or SAVR-SL (1.38  0.38 cm2
nd 0.80  0.21 cm2/m2, respectively) groups. The inci-
ence of severe PPM was higher (p  0.042) in the
AVR-ST (26%) and SAVR-SL (28%) groups than in the
AVI group (11%). As shown in Table 4, the overall
ncidence of prosthetic regurgitation was higher (p  0.0001)
n the PAVI group (78%) than in the SAVR-ST (48%) or
AVR-SL (34%) groups. Mild AR was present in 42% of the
AVI patients compared with 10% and 12% of the SAVR-ST
nd SAVR-SL patients, respectively (p 0.001). Four (8%) of
he PAVI patients had moderate AR at hospital discharge
ompared with none of the SAVR patients (p  0.24). The
R was considered of paravalvular origin in 94%, 56%, and
8% of the cases in the PAVI, SAVR-ST, and SAVR-SL
roups, respectively. Figure 1 shows the absence of any signif-
cant association between the degree of valve oversizing and the
at Baseline
ic Variables at Baseline
AVR-ST (n  50) SAVR-SL (n  50) p Value
75 6* 70 9*† 0.0001
27 (54) 27 (54) 1.000
1.72 0.20 1.74 0.17 0.311
25.7 3.6 27.0 5.1 0.068
20.0 1.6 20.1 1.7 0.779
11.8 1.1 11.7 1.2 0.730
55 15 56 14 0.105
42 16 43 8 0.211
0.68 0.20 0.69 0.24 0.053
0.40 0.12* 0.40 0.14* 0.011
.05) versus SAVR-ST. ‡Matched variables.bles
graph
S
(p  0
implantation; SAVR-SL  surgical aortic valve replacement–stentless
o
a
t
m
g
g
0
S
(
b
t
w
(
n
b
f
c
b
f
f
v
a
p
4
0
f
E
P
w
a
P
a
t
i
w
(
DA
V
AFB
V
1886 Clavel et al. JACC Vol. 53, No. 20, 2009
Percutaneous Versus Surgical Bioprostheses May 19, 2009:1883–91ccurrence and degree of AR after PAVI. The valve size/aortic
nnulus diameter ratio was 1.25  0.14 in cases with no or
rivial AR compared with 1.24  0.09 in cases with mild or
oderate AR (p  0.79).
No significant differences in LVEF were observed among
roups at hospital discharge, but LVEF improved in the PAVI
roup compared with baseline values (LVEF: 5 10%, p
.001), whereas it remained similar to baseline in the
AVR-ST (LVEF: 1  8%, p  0.39) and SAVR-SL
1  13%, p  0.82) groups (p  0.01 for comparison
etween groups) (Fig. 2). The LVEF data grouped according
o baseline LVEF are shown in Table 5. The increase in LVEF
as more pronounced in the 45 patients with reduced LVEF
50%) at baseline compared with the 105 patients with
ormal LVEF (50%) at baseline (p  0.001 for comparison
etween low and normal LVEF patients in all groups).
Doppler echocardiographic data at 6 to 12 months of
ollow-up are shown in Table 3. There were no significant
hanges in mean transvalvular gradient, EOA, and EOAi
etween hospital discharge and 6 to 12 months of
ollow-up in the PAVI and SAVR-ST groups (p  0.15
or all variables in both groups), whereas mean transval-
ular gradient and EOA exhibited a significant reduction
istribution of Label Prosthesis Sizeccording to Type of A rtic B oprosthesis
Table 2 Distribution of Label Prosthesis SizeAccording to Type of Aortic Bioprosthesis
Prosthesis Size
(mm) PAVI SAVR-ST SAVR-SL
19 — 9 (18) —
21 — 20 (40) 17 (34)
23 18 (36) 16 (32) 18 (36)
25 — 5 (10) 13 (26)
26 32 (64) — —
27 — — 2 (4)
alues are n (%).
Abbreviations as in Table 1.
Doppler Echocardiographic Data According to T
Table 3 Doppler Echocardiographic Data Ac
PAVI
LVEF, %
Discharge 59 12
Follow-up 59 17
Mean transaortic gradient, mm Hg
Discharge 10 4*
Follow-up 10 4*
Effective orifice area, cm2
Discharge 1.61 0.
Follow-up 1.50 0.
Indexed effective orifice area, cm2/m2
Discharge 0.90 0.
Follow-up 0.87 0.
Severe prosthesis-patient mismatch, n (%)
Discharge 5 (11)
Follow-up 3 (6)
The p values presented refer to the intergroup comparisons. *Significa
versus PAVI. ‡Significant difference (p  0.05) versus SAVR-ST. §Significant
Abbreviations as in Table 1.nd increase, respectively, in the SAVR-SL group com-
ared with the values at discharge ( mean gradient: 4 
mm Hg, p  0.001; EOA: 0.18  0.36 cm2, p 
.002; and EOAi: 0.1  0.21 cm2/m2, p  0.003). At
ollow-up, transvalvular gradient was higher and EOA and
OAi were smaller in the SAVR-ST group than in the
AVI and SAVR-SL groups, and no significant differences
ere observed regarding these variables between the PAVI
nd SAVR-SL groups. However, the incidence of severe
PM remained higher (p  0.007) in the SAVR-ST (28%)
nd SAVR-SL (20%) groups than in the PAVI group (6%).
The incidence and degree of AR remained similar to
hose at hospital discharge in the 3 groups, with higher
ncidence of mild AR in the PAVI group (46%) compared
ith the SAVR-ST (10%) and SAVR-SL (16%) groups
p  0.001) (Table 4). There were no differences between
f Aortic Bioprosthesis
ng to Type of Aortic Bioprosthesis
SAVR-ST SAVR-SL p Value
56 11 55 14 0.053
62 18 60 16 0.255
13 5*† 14 6*† 0.001
13 5*† 9 4*‡§ 0.001
1.29 0.25*† 1.38 0.38*† 0.0001
1.33 0.28*† 1.57 0.49*‡§ 0.001
0.76 0.16*† 0.80 0.21*† 0.003
0.78 0.17*† 0.90 0.27‡§ 0.019
13 (26)† 14 (28)† 0.042
14 (28)† 10 (20)† 0.007
rence (p  0.05) versus baseline. †Significant difference (p  0.05)
ortic Regurgitation Data at Discharge and atllow-Up G ouped According to Type of Aorticioprosthesis
Table 4
Aortic Regurgitation Data at Discharge and at
Follow-Up Grouped According to Type of Aortic
Bioprosthesis
PAVI SAVR-ST SAVR-SL p Value
Aortic regurgitation
at discharge
None 6 (12) 31 (62)* 33 (66)* 0.0001
Trivial 19 (38) 14 (28) 11 (22)
Mild 21 (42) 5 (10)* 6 (12)*
Moderate 4 (8) 0 (0) 0 (0)
Severe 0 (0) 0 (0) 0 (0)
Aortic regurgitation
at follow-up
None 11 (22) 26 (52)* 33 (66)* 0.0001
Trivial 13 (26) 18 (36) 9 (18)
Mild 23 (46) 5 (10)* 8 (16)*
Moderate 3 (6) 1 (2) 0 (0)
Severe 0 (0) 0 (0) 0 (0)
alues are n (%). *Significant difference (p  0.05) versus PAVI.
Abbreviations as in Table 1.ype o
cordi
*
40*
36*
26*
18*
nt diffe
difference (p  0.05) versus discharge.
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May 19, 2009:1883–91 Percutaneous Versus Surgical Bioprosthesesroups regarding LVEF values at follow-up. The LVEF
emained similar to that at hospital discharge in the PAVI
roup (p  0.10), whereas it increased by 5  10% (p 
.001) and 4  9% (p  0.004) in the SAVR-ST and
AVR-SL groups, respectively, between hospital discharge
nd follow-up (Fig. 2). The increase in LVEF was higher in
he group of 45 patients with low LVEF at baseline
ompared with the group of 105 patients with baseline
VEF within normal values (p  0.001). Table 5 summa-
izes the changes in LVEF between baseline, hospital
ischarge, and follow-up in low and normal LVEF patients
n the 3 aortic bioprosthesis groups.
mall aortic annulus size subgroup. Table 6 and Figure 3
how the data of EOAi and incidence of severe PPM in the 3
ioprosthesis groups according to the size of the patient’s aortic
nnulus. Compared with the SAVR-ST and SAVR-SL
roups, PAVI was associated with a larger EOAi and a lower
ncidence of severe PPM at discharge and at follow-up in the
ubset of patients with aortic annulus diameter 20 mm,
hereas no differences in the incidence of severe PPM were
bserved between groups in patients with aortic annulus 20
m. In the latter subset of patients, the SAVR-SL valve was
ssociated with a larger EOAi at follow-up compared with the
AVI and SAVR-ST groups.
iscussion
he results of this study showed that PAVI with the
ribier-Edwards or Edwards SAPIEN valve was associated
ith lower transprosthetic gradients and higher EOAs early
0
10
20
30
40
50
60
None or trivial aortic regurgitation
Mild aortic regurgitation
Moderate aortic regurgitation
P
er
ce
nt
ag
e 
of
 p
at
ie
nt
s
Valve size / aortic annulus diameter 
1.0-1.19
 (n=16)
1.20-1.27
  (n=17)
1.27-1.65
  (n=17)
p=0.92
Figure 1 Prosthesis Oversizing and Aortic Regurgitation
Incidence and degree of aortic regurgitation at hospital discharge in the percu-
taneous aortic valve implantation (PAVI) patients grouped according to the
degree of prosthesis oversizing with respect to the aortic annulus diameter.
Red bars  no or trivial aortic regurgitation; orange bars  mild aortic regurgi-
tation; green bars  moderate regurgitation.fter the procedure compared with SAVR with the Magnastented) and Freestyle (stentless) valves. At midterm
ollow-up there were no changes in the hemodynamic
arameters of percutaneously implanted valves, which con-
inued to provide a better hemodynamic performance than
urgically implanted stented valves. The superior hemody-
amic results obtained with PAVI translated into a signif-
cant reduction in the incidence of severe PPM at discharge
11%) and at midterm follow-up (6%) compared with the
tented (discharge: 26%; midterm: 28%) and stentless (dis-
harge: 28%; midterm: 20%) surgical valves. PAVI was
ssociated with a marked reduction of severe PPM in
atients with a small (20 mm) aortic annulus; whereas in
atients with a larger annulus, the overall incidence of PPM
as, as expected, much lower, with no significant differences
etween PAVI and SAVR groups. Furthermore, although
o differences were observed between PAVI and SAVR
atients in LVEF values at midterm follow-up, only pa-
ients who had undergone PAVI exhibited a significant
arly (between baseline and hospital discharge) increase in
VEF, and this effect was more pronounced in patients
ith low LVEF at baseline. Finally, the occurrence of any
egree of AR was more common after PAVI (88%) than
fter SAVR (46%) early after the procedure. However, the
egree of residual AR was trivial or mild in the vast majority
91%) of PAVI patients, with no cases of severe AR, and it
emained stable at midterm follow-up.
rosthesis-patient mismatch. Several studies have rec-
gnized the high prognostic relevance of achieving an
ptimal hemodynamic result after aortic valve replacement
1–3,13–16). The presence of severe PPM has been associ-
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Figure 2 LVEF After Aortic Valve Implantation
Changes in left ventricular ejection fraction (LVEF) after aortic valve implan-
tation in the 3 aortic bioprosthesis groups: percutaneous aortic valve
implantation (PAVI) (circles); surgical aortic valve replacement–stentless
valve (SAVR-SL) (squares); and surgical aortic valve replacement–stented
valve (SAVR-ST) (triangles). Error bars represent standard errors of the esti-
mate. *LVEF different in PAVI groups versus other groups (p  0.05).
†LVEF different from baseline group (p  0.005).
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Percutaneous Versus Surgical Bioprostheses May 19, 2009:1883–91ted with lesser improvement in the functional capacity of
he patients (13), lesser regression of LV hypertrophy (14),
igher rates of cardiac failure (16), and higher rates of
erioperative and long-term mortality (2,3,15,16) after
AVR. The Magna and Freestyle valves are among the
ost commonly used stented and stentless bioprostheses for
AVR, and the results of valve hemodynamic performance
bserved in the present study for these 2 types of bio-
rosthesis were consistent with those of previous studies
17–20), although the aortic annulus and bioprosthesis size
ere smaller in the present study. Previous studies have also
eported that the hemodynamic performance of stentless
ioprostheses is generally superior, and accordingly, the
revalence/severity of PPM is lower compared with stented
ioprostheses (18,20,21). However, the implantation of a
tentless bioprosthesis is more complex and requires longer
ardiopulmonary bypass time. The superior hemodynamic
erformance of stentless bioprostheses has been attributed
o better sizing (namely, ability to implant a larger valve in
given aortic annulus), better preservation of the systolic
xpansion of the aortic root and annulus, and continued
mprovement of valve hemodynamics in the 3 to 6 months
fter operation (16,17). That explains why the hemody-
amic performance of the SAVR-SL valve became superior
VEF Data Grouped According to Baseline LVEF (<50% or >50%) a
Table 5 LVEF Data Grouped According to Baseline LVEF (<50%
LVEF at Baseline <50%
PAVI
(n  15)
SAVR-ST
(n  15)
SAVR-SL
(n  15)
Baseline, %
LVEF 33 12 34 10 36 10
Discharge, %
LVEF 48 11* 42 11 41 15
LVEF 15 8 8 7† 5 14†
Follow-up, %
LVEF 53 13* 53 17*‡ 51 15*
LVEF 20 13 19 16 15 18
he p values presented refer to the intergroup comparisons. *Significant difference (p  0.05) v
ischarge.
LVEF  variation of left ventricular ejection fraction from baseline; other abbreviations as in T
ndexed Effective Orifice Area and Incidence of Severe Patient-Prosismatch Group d Ac ording to Aortic A nulus Siz and Type of B
Table 6 Indexed Effective Orifice Area and Incidence of SevereMismatch Grouped According to Aortic Annulus Size a
Annulus Size <2
PAVI
(n  28)
SAVR-ST
(n  28)
Discharge
Indexed effective orifice area, cm2/m2 0.87 0.27 0.74 0.17* 0.
Severe patient-prosthesis mismatch, n (%) 2 (7) 8 (29)*
Mean gradient, mm Hg 9 4 14 5*
Follow-up
Indexed effective orifice area, cm2/m2 0.87 0.19 0.75 0.2* 0.
Severe patient-prosthesis mismatch, n (%) 2 (7) 9 (32)*
Mean gradient, mm Hg 9 4 14 5*Significant difference (p  0.05) versus PAVI. †Significant difference (p  0.05) versus SAVR-ST. ‡Sign
Abbreviations as in Table 1.o that of the SAVR-ST valve and equivalent to that of the
AVI valves after 6 to 12 months. Nonetheless, the results
f the present study showed that the incidence of severe
PM remains high with both stented and stentless biopros-
heses among patients with a small aortic annulus. Lopez
t al. (22) reported a high rate (58%) of severe PPM among
atients with a small aortic root undergoing SAVR with the
reestyle stentless bioprosthesis, and that was associated
ith high (30%) perioperative mortality. Interestingly, the
esults of the present study reveal that the post-operative
mprovement in the valve hemodynamic performance that is
bserved with stentless bioprostheses essentially occurs in
atients with a medium or large aortic annulus, whereas it is
inimal or absent in patients with a small aortic annulus,
ho are precisely those at highest risk for severe PPM. This
bservation may explain why the rate of severe PPM
emained higher in the SAVR-SL group than in the PAVI
roup at 6 to 12 months of follow-up despite significant
mprovement in the mean values of EOA and gradients in
he SAVR-SL group between hospital discharge and
ollow-up.
With the balloon-expandable Cribier-Edwards or Ed-
ards SAPIEN valve, PAVI was associated with excellent
emodynamic results, with a mean residual transprosthetic
ype of Bioprosthesis
50%) and Type of Bioprosthesis
LVEF at Baseline >50%
lue
PAVI
(n  35)
SAVR-ST
(n  35)
SAVR-SL
(n  35) p Value
29 63 5 63 5 63 5 0.800
10 64 6 61 7 59 11 0.062
14 1 6 2 7 4 11 0.114
48 63 7 64 7 64 10‡ 0.089
21 0 7 1 8 1 11 0.473
aseline. †Significant difference (p  0.05) from PAVI. ‡Significant difference (p  0.05) versus
issthesis
ent-Prosthesis
pe of Bioprosthesis
Annulus Size >20 mm
-SL
8) p Value
PAVI
(n  22)
SAVR-ST
(n  22)
SAVR-SL
(n  22) p Value
.15* 0.032 0.94 0.26† 0.78 0.15 0.92 0.22 0.033
)* 0.049 3 (14) 5 (23) 4 (18) 0.583
* 0.0001 10 5 11 4 11 4 0.902
.18* 0.190 0.88 0.17† 0.79 0.13 1.08 0.27*†‡ 0.002
)* 0.007 1 (5) 5 (23) 1 (5)‡ 0.574
†‡ 0.004 10 4† 12 4 7 4*†‡ 0.004nd T
or >
p Va
0.5
0.1
0.0
0.8
0.9
ersus bthesiopro
Pati
nd Ty
0 mm
SAVR
(n  2
71 0
10 (36
16 6
77 0
9 (32
11 4ificant difference (p  0.05) versus discharge.
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May 19, 2009:1883–91 Percutaneous Versus Surgical Bioprosthesesradient of 10 mm Hg and a mean EOA 1.5 cm2.
mportantly, these results were maintained without signifi-
ant changes at 6 to 12 months of follow-up. Several studies
ave reported similar hemodynamic results with PAVI, with
ransprosthetic gradients 11 mm Hg and EOAs 1.5
m2, and no significant changes in the hemodynamic
arameters up to 2-year follow-up (4–9). The present study
as the first to evaluate the incidence of PPM after PAVI
nd to compare these data with those of surgically im-
lanted bioprostheses. The results of this study showed a
ery low incidence of severe PPM, which was much lower
han that observed with surgically implanted stented or
tentless valves. Importantly, this superiority of PAVI in
erms of reduction of PPM was limited to patients with a
mall aortic annulus in whom the incidence of severe PPM
fter PAVI was as low as 7%, compared with a 32% rate
fter SAVR. Whereas valve sizing during SAVR is limited
y the dimensions of the aortic annulus, PAVI is system-
tically performed with an oversized valve, leading to some
istension of the aortic annulus to accommodate the valve
uring balloon expansion. These findings suggest that
xpanding the bioprosthesis against a severely calcified
ative valve (10) does not appear to be a major limiting
actor to PAVI and its hemodynamic outcome. Moreover,
lthough the PAVI valves are stented valves, the stent is
uch thinner than that of the stented valves used for
AVR, and it therefore causes minimal obstruction to blood
ow. Hence, our findings suggest that, compared with
19 - 20
 (n=66)
16 - 18
 (n=18)
p=0.049 at discharge; p=0.007 at 
     (PAVI vs. SAVR-ST and SAVR
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Figure 3 Prosthesis-Patient Mismatch
Incidence of severe prosthesis-patient mismatch (PPM) in the 3 aortic bioprosthes
percutaneous aortic valve implantation (PAVI) (green bars); surgical aortic valve re
ment–stented valve (SAVR-ST) (brown bars).AVR, PAVI provides better results in terms of valve EOA, sransprosthetic gradient, and prevention of PPM, especially
or patients with a small aortic annulus. Recent studies have
eported that severe PPM has less impact on clinical
utcomes in elderly patients compared with younger ones
23,24); and, conversely, it has been shown that the clinical
mpact of PPM is much more pronounced in patients with
re-existing LV systolic dysfunction irrespective of age
3,24). Hence, it remains uncertain whether or not the lower
ncidence of severe PPM associated with PAVI will trans-
ate into significantly better clinical outcomes for this
opulation, which includes a high proportion of both elderly
atients and patients with reduced LVEF. Future prospec-
ive randomized studies such as the ongoing PARTNER
Placement of Aortic Transcatheter Valves) trial will pro-
ide an opportunity to address this question.
mprovement in LVEF. Consistent with the results of the
resent study, Cribier et al. (4) and Webb et al. (5) have
reviously reported that PAVI was associated with a signif-
cant increase in LVEF (5%) as early as 1 week after the
rocedure, and that this improvement was even greater
15%) among patients with low LVEF before the inter-
ention (4). The present study further showed that this early
mprovement was greater than that observed after SAVR,
specially in patients with LVEF 50%. Both the better
emodynamic results leading to a lower LV afterload and
he avoidance of cardiopulmonary bypass in the PAVI
roup might have been involved in this early improvement
n LVEF that was not observed with SAVR (13,25). Future
21 - 22
 (n=48)
23 - 25
 (n=18)
w-up
p=NS
PAVI
SAVR-ST
SAVR-SL
m)
Follow-up
Discharge
ps at hospital discharge and at follow-up according to the aortic annulus size:
ent–stentless valve (SAVR-SL) (blue bars); and surgical aortic valve replace-follo
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placemtudies are needed to determine whether this early and faster
r
t
g
s
A
v
f
o
c
b
c
t
p
t
a
s
v
n
o
p
d
o
i
i
F
m
w
m
b
(
t
t
w
s
F
e
l
l
p
w
r
n
l
p
d
i
t
S
w
f
p
p
p
r
s
r
w
w
v
h
S
b
s
p
p
f
h
m
c
p
r
c
r
A
T
S
t
R
Q
S
j
R
1
1890 Clavel et al. JACC Vol. 53, No. 20, 2009
Percutaneous Versus Surgical Bioprostheses May 19, 2009:1883–91ecovery of LV systolic function increase associated with PAVI
ranslates into a reduction of the high perioperative mortality
enerally observed in the high-risk group of patients with
evere aortic stenosis and low LVEF undergoing SAVR.
R. PAVI has been associated with a high rate of paraval-
ular prosthetic regurgitation, with an incidence ranging
rom 65% to 85% (4–8), which is much higher than that
bserved after SAVR (26,27). The presence of the severely
alcified native valve between the percutaneously implanted
ioprosthesis and the aortic annulus probably precludes a
omplete sealing of the paravalvular space, and thereby leads
o some degree of AR in most cases. Interestingly, the
resent study showed that greater oversizing of the percu-
aneous valve with respect to the aortic annulus was not
ssociated with lesser incidence and severity of AR (Fig. 1),
uggesting that other mechanisms such as the degree of
alve calcification or leaflet-commissural deformation of the
ative valve (10) might be more important than the amount
f valve-aortic annulus stretching by the stent of the
ercutaneous bioprosthesis. Importantly, and also in accor-
ance with the results of the present study, the vast majority
f paravalvular leaks after PAVI were trivial or mild, with an
ncidence of moderate AR ranging from 0% to 26% and an
ncidence of severe AR ranging from 0% to 10% (4–9).
urthermore, the degree of paravalvular AR generally re-
ains stable or even improves slightly over time (4–8), as
as also seen in the present study. Also, the presence of
ild-to-moderate paravalvular leaks after PAVI has not
een associated with any clinical consequences at midterm
1- to 2-year) follow-up (4–8). Rallidis et al. (26) showed
hat paraprosthetic regurgitation occurred in up to 48% of
he patients after SAVR. Most of these paravalvular leaks
ere trivial or mild and did not progress or have any
ignificant impact on clinical outcomes at 5-year follow-up.
urthermore, it has been well demonstrated that the pres-
nce of mild-to-moderate AR is usually well tolerated for a
ong time (28). Larger studies with clinical end points and
ong-term follow-up will have to determine the degree of
rogression and potential clinical consequences associated
ith these paravalvular leaks after PAVI. Also, future
esearch efforts should focus on improving this valve tech-
ology to further reduce the occurrence of paravalvular
eaks. In the meantime, given the uncertainty about the
rogression rate of the paravalvular leaks and about the
urability of the percutaneously implanted prosthetic valves
n the long-term, these valves should be used with caution in
he patients who have a long life expectancy.
tudy limitations. This study included a series of patients
ho underwent PAVI reaching the 6 to 12 months of
ollow-up and excluded patients who died during the
erioperative period or within the few months after the
rocedure and those with incomplete follow-up data. This
atient selection might have partially biased the results
egarding PAVI, but this might have also occurred to the
ame extent with SAVR patients. Also, no clinical data
egarding patients’ functional capacity and quality of lifeere included in the study. The reason was that all patients
ho underwent PAVI were considered nonoperable or at
ery high surgical risk, implying that they were older and
ad more comorbidities than patients who underwent
AVR. Considering these significant baseline differences
etween groups, we think that comparing clinical data
uch as functional class between PAVI and SAVR
atients might have been misleading. The follow-up
eriod was relatively short, and future studies with longer
ollow-up should be carried out to determine whether the
emodynamic performance of percutaneous valves re-
ains stable at long-term follow-up. Finally, this was a
ase-control study, and although the data had been
rospectively gathered in all patients, future prospective
andomized studies such as the PARTNER trial, which
ompares PAVI to SAVR, will have to confirm these
esults.
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